Bleeding risk with dabigatran in the frail elderly

New England Journal of Medicine

Volumn 366, Issue 9, 2012, Pages 864-866

  Harper, Paul ^a   Young, Laura ^b   Merriman, Eileen ^c  

^a PALMERSTON NORTH HOSPITAL   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX;

BLEEDING; BRAIN HEMORRHAGE; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; EVENING DOSAGE; FRAIL ELDERLY; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HEMATEMESIS; HEMATURIA; HEMOPTYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LETTER; MORNING DOSAGE; MUCOSAL BLEEDING; NEW ZEALAND; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; STROKE; SUBDURAL HEMATOMA; THROMBOCYTE TRANSFUSION; VAGINA BLEEDING;

EID: 84857853180     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1112874     Document Type: Letter

References (3)

1. Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011;124:824-9.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. [Erratum, N Engl J Med 2010;363:1877.]
3. Boehringer Ingelheim. Advisory committee briefing document submitted to the Food and Drug Administration. August 2010 (http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf).